Apellis Pharmaceuticals Launch Update of SYFOVRE®
On October 5, 2023, Apellis Pharmaceuticals (APLS) provided an update on the launch of its product SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
About Geographic Atrophy
GA is an advanced form of age-related macular degeneration and a leading cause of blindness, impacting more than one million Americans . . .